簡歷：
1985年—1989年在湖南醫科大學攻讀藥理學專業博士（畢業論文課題在美國橡樹嶺聯合大學完成）；1989年—1992年在美國陸軍感染性疾病研究院承擔美國國家科學院博士後課題研究；1993年晉升湖南醫科大學教授和1996年遴選為藥理學博導； 1996年—2001年在美國Leukosite和Mellennium藥業公司擔任藥理學資深研究員； 2001年—2006在美國Curis公司擔任藥理學總監和資深總監；2006年—2011年擔任Curis公司副總裁和資深副總裁 。
2012年入選Marquis（第66版）美國名人錄 ；個人資訊載入福布斯 ；2013年入選《科學中國人》年度人物 ；發表了29個國際專利，並獲得了28個美國授權發明專利 ；發表了30多篇學術論文。
發明專利（美國授權）
Cai, X. Zhai, H. Lai, C. Qian, C. Bao, Rudi. Phosphoinositide 3-kinase inhibitor with a zinc binding moiety 8,906,909(2014)
Cai, X. Qian, C. Zhai, H.Tartrate salts of quinazoline based EGFR inhibitors containing a zinc binding moiety 8,846,912 (2014)
Cai, X. Qian, C. Fused amino pyridines for the treatment of brain tumors. US Patent Number 8,722,703 (2014)
Cai, X. Zhai, H. Lai, C. Qian, C. Bao, Rudi. Phosphoinositide 3-kinase inhibitor with a zinc binding moiety 8,710,219 (2014)
Qian, C. Cai, X. Zhai, H. CDK inhibitors. US Patent Number 8,691,820 (2014)
Qian, C. Cai, X. Could, S. Zhai, H. Quinazoline based EGFR inhibitors containing a zinc binding moiety. US Patent Number 8,604,044 (2013)
Cai, X. Qian, C. Zhai, H. Fused amino pyridine as HSP90 inhibitors. US Patent Number 8,586,605 (2013)
Qian, C. Cai, X. Zhai, H. CDK inhibitors containing a zinc binding moiety. US Patent Number 8,563,741 (2013)
Cai, X. Qian, C. Zhai, H. Bao, R. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety. US Patent Number 8,518,910 (2013)
Cai, X. Zhai, H. Lai, C. Qian, C. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety. US Patent Number 8,461,157 (2013)
Qian, C. Cai, X. Gould, G. Quinazoline based EGFR inhibitors containing a zinc binding moiety. US Patent Number 8,455,506 (2013)
Cai, X. Qian, C. Gould, G. Zhai, H. Tyrosine kinase inhibitors containing a zinc binding moiety. US Patent Number 8,426,419 (2013)
Cai, X. Zhai, H. Lai, C-J. and Qian, C. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety. US Patent Number 8,367,663 (2013)
Qian, C. and Cai, X. Quinazoline based EGFR inhibitors. US Patent Number 8,349,856 (2013)
Cai, X. Qian, C. and Zhai, H. Fused amino pyridine as HSP90 inhibitors. US Patent Number 8,324,240 (2012)
Cai, X. Qian, C. and Gould S. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety. US Patent Number 8,273,785 (2012)
Cai, X. Qian, C. Zhai, H. and Bao, Rudi. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety . US Patent Number 8119616 (2012)
Qian, C. and Cai, X. Quinazoline based EGFR inhibitors. US Patent Number 7977347 (2011)
Cai, X. Qian, C. and Gould, S. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety. US Patent Number 7928136 (2011)
Cai, X. Qian, C. Gould, S. and Zhai, H. Tyrosine kinase inhibitors containing a zinc binding moiety. US Patent Number 7888361 (2011)
Cai, X. Qian, C. and Zhai, H . Tartrate salts of quinazoline based EGFR inhibitors containing a zinc binding moiety. Patent Number 7846938 (2010)
Cai, X. Qian, C. and Gould, S. Quinazoline based EGFR inhibitors containing a zinc binding moiety. Patent Number 7547781 (2009)
Cai, X. Fura, A. and Qian, C. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders. U.S. Patent Number 6569895 (2003)
Qian, C. Li, T. and Biftu, J. Epibatidine and derivatives thereof as cholinergic agonists and antagonists. U.S. Patent Number 6077846 (2000)
Qian, C. Li, T. and Biftu, J. Epibatidine and derivatives thereof as cholinergic agonists and antagonists. U.S. Patent Number 6177451 (2001)
Cai, X. Fura, A. and Qian, C. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders. U.S. Patent Number 6025384 (2000)
Cai, X. Fura, A. and Qian, C. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders. U.S. Patent Number 5750565 (1998)
Cai, X., Fura, A. and Qian, C. Compounds and methods for the treatment ofcardiovascular, inflammatory and immune disorders. U.S. Patent Number 5703093 (1997)
1.Cai, X. Zhai, H. Lai, C. Qian, C. Bao, Rudi. Phosphoinositide 3-kinase inhibitor with a zinc binding moiety 8,906,909(2014)
2.Cai, X. Qian, C. Zhai, H.Tartrate salts of quinazoline based EGFR inhibitors containing a zinc binding moiety 8,846,912 (2014)
3.Cai, X. Qian, C. Fused amino pyridines for the treatment of brain tumors. US Patent Number 8,722,703 (2014)
4.Cai, X. Zhai, H. Lai, C. Qian, C. Bao, Rudi. Phosphoinositide 3-kinase inhibitor with a zinc binding moiety 8,710,219 (2014)
5.Qian, C. Cai, X. Zhai, H. CDK inhibitors. US Patent Number 8,691,820 (2014)
6.Qian, C. Cai, X. Could, S. Zhai, H. Quinazoline based EGFR inhibitors containing a zinc binding moiety. US Patent Number 8,604,044 (2013)
7.Cai, X. Qian, C. Zhai, H. Fused amino pyridine as HSP90 inhibitors. US Patent Number 8,586,605 (2013)
8.Qian, C. Cai, X. Zhai, H. CDK inhibitors containing a zinc binding moiety. US Patent Number 8,563,741 (2013)
9.Cai, X. Qian, C. Zhai, H. Bao, R. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety. US Patent Number 8,518,910 (2013)
10.Cai, X. Zhai, H. Lai, C. Qian, C. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety. US Patent Number 8,461,157 (2013)
11.Qian, C. Cai, X. Gould, G. Quinazoline based EGFR inhibitors containing a zinc binding moiety. US Patent Number 8,455,506 (2013)
12.Cai, X. Qian, C. Gould, G. Zhai, H. Tyrosine kinase inhibitors containing a zinc binding moiety. US Patent Number 8,426,419 (2013)
13.Cai, X. Zhai, H. Lai, C-J. and Qian, C. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety. US Patent Number 8,367,663 (2013)
14.Qian, C. and Cai, X. Quinazoline based EGFR inhibitors. US Patent Number 8,349,856 (2013)
15.Cai, X. Qian, C. and Zhai, H. Fused amino pyridine as HSP90 inhibitors. US Patent Number 8,324,240 (2012)
16.Cai, X. Qian, C. and Gould S. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety. US Patent Number 8,273,785 (2012)
17.Cai, X. Qian, C. Zhai, H. and Bao, Rudi. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety . US Patent Number 8119616 (2012)
18.Qian, C. and Cai, X. Quinazoline based EGFR inhibitors. US Patent Number 7977347 (2011)
19.Cai, X. Qian, C. and Gould, S. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety. US Patent Number 7928136 (2011)
20.Cai, X. Qian, C. Gould, S. and Zhai, H. Tyrosine kinase inhibitors containing a zinc binding moiety. US Patent Number 7888361 (2011)
21.Cai, X. Qian, C. and Zhai, H . Tartrate salts of quinazoline based EGFR inhibitors containing a zinc binding moiety. Patent Number 7846938 (2010)
22.Cai, X. Qian, C. and Gould, S. Quinazoline based EGFR inhibitors containing a zinc binding moiety. Patent Number 7547781 (2009)
23.Cai, X. Fura, A. and Qian, C. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders. U.S. Patent Number 6569895 (2003)
24.Qian, C. Li, T. and Biftu, J. Epibatidine and derivatives thereof as cholinergic agonists and antagonists. U.S. Patent Number 6077846 (2000)
25.Qian, C. Li, T. and Biftu, J. Epibatidine and derivatives thereof as cholinergic agonists and antagonists. U.S. Patent Number 6177451 (2001)
26.Cai, X. Fura, A. and Qian, C. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders. U.S. Patent Number 6025384 (2000)
27.Cai, X. Fura, A. and Qian, C. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders. U.S. Patent Number 5750565 (1998)
28.Cai, X., Fura, A. and Qian, C. Compounds and methods for the treatment ofcardiovascular, inflammatory and immune disorders. U.S. Patent Number 5703093 (1997)
過去5年主要論文和著作（第一作者和資深作者）
Qian C, Lai CJ, Bao R, Wang DG, Wang J, Xu GX, Atoyan R, Qu H, Yin L, Samson M, Forrester J, Zifcak B, Ma A, DellaRocca S, Borek M, Zhai HX , Cai X, Vio M. Cancer Network Disruption with a Single Molecule Targeting Histone Deacetylase Epigenatics and PI3K Pathway. Clin Cancer Res 18: 4104-4113, 20122.
Cai X, Qian C. Chapter 14 Discovery of HDAC-Inhibiting Multi-Target Inhibitors. In Designing Multi-Target Drugs. RSC Publishing Editor(s): Morphy J. R, Harris C J. 221-242
Lai CJ, Bao R, Tao X, Wang J, Atoyan R, Qu H, Wang DG, Yin L, Samson M, Forrester J, Zifcak B, Xu GX, DellaRocca S, Zhai HX, Cai X, Munger WE, Keegan M, Pepicelli CV, Qian C. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res70:3647-56, 2010
Cai X, Zhai HX, Wang J, Forrester J, Qu H, Yin L, Lai CJ, Bao R, Qian C. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N- hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J Med Chem. 53:2000-2009, 2010
Bao R, Lai CJ, Wang DG, Qu H, Yin L, Zifcak B, Tao X, Wang J, Atoyan R, Samson M, Forrester J, Xu GX, DellaRocca S, Borek M, Zhai HX, Cai X, Qian C. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer. Mol Cancer Ther. 8:3296-3306, 2009
Bao R, Lai CJ, Qu H, Wang D, Yin L, Zifcak B, Atoyan R, Wang J, Samson M, Forrester J, DellaRocca S, Xu GX, Tao X, Zhai HX, Cai X, Qian C. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy. Clin Cancer Res. 15:4046-57, 2009.
1.Qian C, Lai CJ, Bao R, Wang DG, Wang J, Xu GX, Atoyan R, Qu H, Yin L, Samson M, Forrester J, Zifcak B, Ma A, DellaRocca S, Borek M, Zhai HX , Cai X, Vio M. Cancer Network Disruption with a Single Molecule Targeting Histone Deacetylase Epigenatics and PI3K Pathway. Clin Cancer Res 18: 4104-4113, 20122.
2.Cai X, Qian C. Chapter 14 Discovery of HDAC-Inhibiting Multi-Target Inhibitors. In Designing Multi-Target Drugs. RSC Publishing Editor(s): Morphy J. R, Harris C J. 221-242
3.Lai CJ, Bao R, Tao X, Wang J, Atoyan R, Qu H, Wang DG, Yin L, Samson M, Forrester J, Zifcak B, Xu GX, DellaRocca S, Zhai HX, Cai X, Munger WE, Keegan M, Pepicelli CV, Qian C. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res70:3647-56, 2010
4.Cai X, Zhai HX, Wang J, Forrester J, Qu H, Yin L, Lai CJ, Bao R, Qian C. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N- hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J Med Chem. 53:2000-2009, 2010
5.Bao R, Lai CJ, Wang DG, Qu H, Yin L, Zifcak B, Tao X, Wang J, Atoyan R, Samson M, Forrester J, Xu GX, DellaRocca S, Borek M, Zhai HX, Cai X, Qian C. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer. Mol Cancer Ther. 8:3296-3306, 2009
6.Bao R, Lai CJ, Qu H, Wang D, Yin L, Zifcak B, Atoyan R, Wang J, Samson M, Forrester J, DellaRocca S, Xu GX, Tao X, Zhai HX, Cai X, Qian C. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy. Clin Cancer Res. 15:4046-57, 2009.
